Everything I read about Essa Pharma (NASDAQ: EPIX) sounds positive. They claim to have a game-changing prostate cancer technology and significant news ahead. But it is very difficult to buys shares because the 1M float seems tightly held. Four institutions (BVF, Clarus, Omega, Eventide) own 90% of common paid well over $12 for their shares, an analyst has a...
